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A B S T R A C T
Objectives. This study examined
the association between menopausal
hormones and breast cancer in a bira-
cial population.
Methods. Logistic regression was
used to calculate odds ratios for breast
cancer associated with hormone use
among 397 cases and 425 controls, all
menopausal women.
Results. Odds ratios for ever use
of hormones were 0.8 (95% conf i-
dence interval [CI] = 0.5, 1.2) for
White women and 0.7 (95% CI = 0.4,
1.2) for Black women. Risk was not
increased with longer duration of use
or more recent use.
Conclusions. Breast cancer risk
was not increased among White or
Black women who used menopausal
hormones, despite patterns of use vary-
ing considerably between races. (Am J
Public Health. 2000;90:966–971)
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The relationship between menopausal
hormones and breast cancer has been investi-
gated extensively, yet an increased risk has
not been shown consistently.1 Nonetheless,
several meta-analyses and a collaborative re-
analysis of 51 studies concluded that long-
term hormone use increases risk by 20% to
35%, particularly among current users.2–5
Among the many studies of this associa-
tion, none has focused on Black women. The
risk associated with hormone use may differ
between Black and White women.
Black women more frequently have es-
trogen receptor-negative breast cancers.6
Genotype frequencies for certain estrogen-
metabolizing enzymes vary between races,7,8
although the significance of these observa-
tions is currently unknown. Finally, Black
women have a high prevalence of obesity,9
and body mass index (BMI) reportedly modi-
fies the relationship between hormones and
breast cancer, with stronger associations
among leaner women.5
We examined the association between
menopausal hormones and breast cancer in a
case–control study in North Carolina. Ap-
proximately 40% of the study population
were Black women, so we had an opportunity
to compare patterns of hormone use and the
association with breast cancer between racial
groups.
Methods
The Carolina Breast Cancer Study was a
population-based, case–control study.10,11 Eli-
gible cases were aged 20 to 74 years and were
first given the diagnosis of invasive breast
cancer between 1993 and 1996. Black women
and women younger than 50 were oversam-
pled with a modification of randomized re-
cruitment.12 Controls were selected from the
Division of Motor Vehicle (ages 20–64) and
Medicare (ages 65–74) lists. Sampling frac-
tions based on race and 5-year age groups
were implemented to ensure approximate fre-
quency matching to cases. Women of all
races were included, but White and Black
women constituted the vast majority of the
population. Other races, representing 1.6% of
the study population, were included with
White women for race-specific analyses.
Among women who were located and
eligible, 77% of the cases and 68% of the
controls were interviewed.13 Case response
rates ranged from 83% for White women
younger than 50 years to 68% for Black
women 50 years or older. Control response
rates ranged from 73% for White women
younger than 50 years to 59% for Black
women 50 years or older.
Participants were interviewed in person
to obtain data on established and suspected
breast cancer risk factors. Questions on non-
contraceptive hormones ascertained the type
of hormone, dose, age at first and last use,
duration of use, and treatment regimen. A
pictorial display of commonly prescribed es-
trogens and progestins helped participants to
recall hormonal information.
The analyses examined 397 cases and
425 controls who were menopausal. We in-
cluded women who reported natural meno-
pause, bilateral oophorectomy, or menopause
caused by chemotherapy or radiation unre-
lated to breast cancer. Women who had a hys-
terectomy without bilateral oophorectomy
were included if they were 50 years or older.
We also included women who were presum-
ably menopausal but could not specify a date
for cessation of menses because they started
hormones before their periods had stopped
completely.
We used the SAS GENMOD proce-
dure (SAS Institute Inc, Cary, NC) to calcu-
late odds ratios (ORs) and 95% confidence
intervals (CIs) with logistic regression mod-
els. Women who used oral or transdermal
hormones for 3 months or longer were cate-
gorized as ever users. Covariates included in
multivariate models were age (in 5-year in-
crements), type of menopause (natural, bi-
lateral oophorectomy, or other), age at
menarche, number of full-term pregnancies,
lactation history, history of breast cancer in
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a first-degree relative, BMI quartiles, edu-
cation, alcohol consumption, and smoking.
A term for race was included in models not
stratified by race. Age at menopause was
examined as an additional covariate, but
women whose age at menopause was un-
known were excluded from these models.
Odds ratios from models including age at
menopause were not substantially changed
from those without it; thus, results are pre-
sented for the latter models.
Results
Characteristics of hormone users and
nonusers among control women are shown in
Table 1. The odds ratios show the association
between each covariate and hormone use.
Ever use of hormones was reported more
commonly by White (65%) than by Black
(39%) controls. Mean duration of use was
90 months for White women and 63 months
for Black women. Among both races, hor-
mone use was more common among women
who had undergone bilateral oophorectomy,
nulliparous women, women who had never
lactated, and women who drank alcohol. Oral
contraceptive use, higher education, and
smoking were associated with hormone use
only among Black women, whereas history
of breast biopsy was associated with hor-
mone use only among White women. The as-
sociations with family history and age at
menarche were in opposite directions for
TABLE 1—Selected Characteristics of Hormone Users and Nonusers Among Controls, by Race: Carolina Breast Cancer Study
White Women Black Women
Users (n=159) Nonusers (n=85) Users (n=71) Nonusers (n=110)
% % ORa (95% CI) % % ORa (95% CI)
Age at selection, y
≤40 1.3 1.2 1.4 0.9
41–50 20.1 12.9 36.6 10.0
51–60 35.2 20.0 26.8 34.6
61–74 43.4 65.9 35.2 54.6
Type of menopause
Natural 32.7 69.4 1.0 12.7 65.5 1.0
Bilateral oophorectomy 30.2 5.9 9.5 (3.5, 26.0) 66.2 12.7 23.1 (9.2, 58.4)
Otherb 37.1 24.7 3.1 (1.7, 5.9) 21.1 21.8 5.1 (1.9, 13.2)
No. of full-term pregnancies
0 10.1 5.9 1.0 11.3 10.9 1.0
1 13.2 10.6 0.8 (0.2, 2.9) 14.1 14.6 0.7 (0.2, 2.4)
2 39.6 34.1 0.6 (0.2, 1.9) 18.3 15.5 0.8 (0.2, 2.7)
≥3 37.1 49.4 0.5 (0.2, 1.6) 56.3 59.1 0.8 (0.3, 2.2)
Breast-fed
Never 64.8 51.8 1.0 62.0 45.5 1.0
Ever 35.2 48.2 0.6 (0.4, 1.1) 38.0 54.5 0.7 (0.4, 1.4)
Age at menarche, y
≤11 15.8 18.8 1.0 26.8 16.5 1.0
12–13 62.0 56.5 1.4 (0.7, 2.9) 46.5 47.7 0.6 (0.3, 1.3)
≥14 22.2 24.7 1.4 (0.6, 3.2) 26.8 35.8 0.5 (0.2, 1.2)
History of breast cancer 
in first-degree relative
No 88.0 80.5 1.0 84.3 87.2 1.0
Yes 12.0 19.5 0.6 (0.3, 1.3) 15.7 12.8 1.6 (0.6, 3.9)
History of breast biopsy
No 71.7 80.0 1.0 82.9 86.2 1.0
Yes 28.3 20.0 1.7 (0.9, 3.3) 17.1 13.8 1.1 (0.5, 2.7)
Oral contraceptive use
Never 49.4 54.1 1.0 46.5 74.5 1.0
Ever 50.6 45.9 0.8 (0.4, 1.5) 53.5 25.5 2.4 (1.2, 4.8)
Education, y
<12 15.1 17.7 1.0 29.6 53.6 1.0
12 28.3 29.4 1.0 (0.4, 2.2) 38.0 15.5 3.4 (1.5, 7.7)
>12 56.6 52.9 1.1 (0.5, 2.3) 32.4 30.9 1.4 (0.6, 3.0)
BMI quartile, kg/m2
1st (<24.00) 36.1 31.8 1.0 11.4 11.9 1.0
2nd (24.00–27.69) 30.4 24.7 1.1 (0.5, 2.1) 22.9 18.4 1.0 (0.3, 3.2)
3rd (27.70–32.49) 20.3 32.9 0.5 (0.3, 1.1) 30.0 22.0 1.1 (0.4, 3.2)
4th (≥32.50) 13.3 10.6 1.0 (0.4, 2.5) 35.7 47.7 0.6 (0.2, 1.7)
Alcohol use
Never 33.3 42.3 1.0 28.2 49.1 1.0
Ever 66.7 57.6 1.3 (0.7, 2.3) 71.8 50.9 2.0 (1.0, 3.9)
Smoker
Never 50.3 41.2 1.0 47.9 70.0 1.0
Ever 49.7 58.8 0.7 (0.4, 1.2) 52.1 30.0 2.3 (1.2, 4.4)
Note. BMI=body mass index; OR=odds ratio; CI=confidence interval.
aAdjusted for age.
bIncludes women who had a hysterectomy without bilateral oophorectomy, women who underwent menopause caused by chemotherapy 
or radiation unrelated to breast cancer, and women who began taking hormones before their periods had stopped completely.
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Black and White women. BMI was not asso-
ciated with hormone use in either race.
Table 2 presents characteristics of cases
and controls stratified by race. Among both
races, older age at menopause, natural meno-
pause, earlier age at menarche, and never
breast-feeding were more common among
cases than controls. Nulliparity and family
history of breast cancer were associated with
breast cancer among White but not among
Black women. Previous breast biopsy, oral
contraceptive use, education, BMI, alcohol
use, and smoking history were not associated
with breast cancer in either race.
Odds ratios and 95% confidence inter-
vals associated with hormone use for White
and Black women are shown in Table 3. Ever
use of hormones did not increase breast can-
cer risk for either White (OR=0.8, 95% CI=
0.5, 1.2) or Black women (OR=0.7, 95% CI=
0.4, 1.2). No consistent trends of increasing
risk with longer duration of use or more re-
cent use were found. Odds ratios were similar
for women who used estrogen alone and those
who used estrogen plus progestin. These
analyses included both women who had al-
ways used progestin with estrogen and those
who had used unopposed estrogen at some
point. Odds ratios greater than 1 were ob-
served for women who used progestin alone,
although few women were in that category.
Among women reporting estrogen use,
73% used only conjugated estrogens, and an
additional 14% used conjugated estrogens
and other estrogens. Consequently, we had
limited power to explore variations in risk by
TABLE 2—Selected Characteristics of Cases and Controls, by Race: Carolina Breast Cancer Study
White Women Black Women
Cases (n=222) Controls (n=244) Cases (n=175) Controls (n=181)
% % ORa (95% CI) % % ORa (95% CI)
Type of menopause
Natural 60.4 45.5 1.0 54.3 44.8 1.0
Bilateral oophorectomy 16.7 21.7 0.5 (0.3, 0.9) 20.0 33.7 0.5 (0.3, 0.8)
Other 23.0 32.8 0.5 (0.3, 0.8) 25.7 21.6 1.0 (0.6, 1.7)
Age at menopause, y
<45 35.6 43.8 1.0 47.7 50.0 1.0
45–54 58.8 50.0 1.6 (1.0, 2.3) 44.2 45.5 1.0 (0.7, 1.6)
≥55 5.6 6.2 1.2 (0.5, 2.8) 8.1 4.6 1.8 (0.7, 4.6)
Age at menarche, y
≤11 19.8 16.9 1.0 27.0 20.6 1.0
12–13 58.6 60.1 0.8 (0.5, 1.3) 47.1 47.2 0.7 (0.4, 1.3)
≥14 21.6 23.1 0.8 (0.4, 1.4) 25.9 32.2 0.6 (0.3, 1.0)
No. of full-term pregnancies
0 14.0 8.6 1.0 12.6 11.1 1.0
1 15.8 12.3 0.8 (0.4, 1.7) 13.1 14.4 0.8 (0.4, 1.9)
2 33.8 37.7 0.6 (0.3, 1.1) 18.3 16.6 1.0 (0.5, 2.3)
≥3 36.5 41.4 0.6 (0.3, 1.1) 56.0 58.0 0.9 (0.5, 1.7)
Breast-fed
Never 67.6 60.2 1.0 57.1 51.9 1.0
Ever 32.4 39.8 0.7 (0.5, 1.0) 42.9 48.1 0.8 (0.5, 1.2)
History of breast cancer 
in first-degree relative
No 80.8 85.3 1.0 90.0 86.1 1.0
Yes 19.2 14.7 1.4 (0.8, 2.3) 10.0 14.0 0.7 (0.4, 1.3)
History of breast biopsy
No 74.8 74.6 1.0 84.4 84.9 1.0
Yes 25.2 25.4 1.0 (0.7, 1.6) 15.6 15.1 1.1 (0.6, 1.9)
Oral contraceptive use
Never 51.8 51.0 1.0 65.1 63.5 1.0
Ever 48.2 49.0 1.0 (0.7, 1.6) 34.9 36.5 1.0 (0.6, 1.6)
Education, y
<12 16.7 16.0 1.0 42.3 44.2 1.0
12 29.3 28.7 1.0 (0.6, 1.7) 26.3 24.3 1.2 (0.7, 2.1)
>12 54.1 55.3 0.9 (0.6, 1.6) 31.4 31.5 1.1 (0.7, 1.9)
BMI quartile, kg/m2
1st (<24.00) 37.3 34.6 1.0 15.5 11.7 1.0
2nd (24.00–27.69) 34.6 28.4 1.2 (0.8, 1.9) 18.5 20.1 0.7 (0.3, 1.5)
3rd (27.70–32.49) 16.6 24.7 0.6 (0.4, 1.1) 33.9 25.1 1.0 (0.5, 2.1)
4th (≥32.50) 11.5 12.4 0.8 (0.4, 1.6) 32.1 43.0 0.6 (0.3, 1.1)
Alcohol use
Never 34.7 36.5 1.0 40.0 40.9 1.0
Ever 65.3 63.5 0.9 (0.6, 1.4) 60.0 59.1 0.9 (0.6, 1.4)
Smoker
Never 45.1 47.1 1.0 55.4 61.3 1.0
Ever 55.0 52.9 0.9 (0.7, 1.4) 44.6 38.7 0.8 (0.5, 1.2)
Note. BMI=body mass index; OR=odds ratio; CI=confidence interval.
aAdjusted for age.
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type of estrogen. Increased risk was sug-
gested among White women who used trans-
dermal estrogen, but the analysis was based
on very few women. Analyses restricted to
conjugated estrogen users showed little evi-
dence of a dose–response relationship.
Analyses stratified by BMI did not show
greater risk for thinner women (BMI less
than the race-specific median value among
controls). Among Black women, odds ratios
for breast cancer were 0.4 (95% CI = 0.2,
0.9) for thinner women and 1.8 (95% CI =
0.7, 4.3) for heavier women. Among White
women, odds ratios were 0.9 (95% CI=0.5,
1.6) and 0.7 (95% CI=0.4, 1.3) for thinner
and heavier women, respectively.
Discussion
Overall, we found essentially no evi-
dence of increased breast cancer risk among
menopausal hormone users in this biracial
population. Odds ratios for ever use of hor-
mones were less than 1 for both Black and
White women; however, the confidence in-
tervals around these point estimates were
consistent with modestly increased risk.
Similarly, there was little suggestion of in-
creased risk within subgroup analyses exam-
ining duration or recency of use, type of es-
trogen, or dose of conjugated estrogens. The
risks were similar for women who used es-
trogen alone and those who used estrogen
plus progestin.
This report, to our knowledge, is the first
to provide data on menopausal hormones and
breast cancer among Black women. Race-
specific analyses did not reveal important dif-
ferences between Black and White women. A
possible exception is the finding of increased
risk among heavier Black women. This result,
based on strata with relatively few women,
was unexpected given the conclusions of the
collaborative analysis5 and should be inter-
preted cautiously.
A source of bias may have been response
rate differences between cases and controls
and the association between nonparticipation
and hormone use. Women who declined an
in-person interview were asked to complete a
brief telephone survey on basic breast cancer
risk factors. Both case and control women
who responded to only the telephone survey
reported hormone use less commonly than
women who completed the in-person inter-
view.13 Assuming that hormone use was simi-
larly low among women who completely re-
fused to participate, the observed odds ratios
were likely biased away from the null, result-
ing in stronger inverse relationships, because
response rates were lower among controls
than cases. This bias may have been most pro-
nounced among Black women because re-
sponse rates were lowest among older Black
controls. However, it seems unlikely that this
bias would have been large enough to obscure
a significantly increased risk of breast cancer
associated with hormones, especially because
the prevalence of hormone use in our popula-
tion was similar to that reported in 2 surveys
of Black women.14,15
TABLE 3—Odd Ratios (ORs) for Breast Cancer Associated With Use of Menopausal Hormones, by Race: Carolina Breast 
Cancer Study
All Women White Women Black Women
Cases Controls Cases Controls Cases Controls 
(n=384) (n=420) (n=217) (n=242) (n=167) (n=178)
% % ORa (95% CI) % % ORb (95% CI) % % ORb (95% CI)
Never 56.3 45.9 1.0 45.2 35.1 1.0 70.7 60.7 1.0
Ever 43.8 54.1 0.8 (0.5, 1.1) 54.8 64.9 0.8 (0.5, 1.2) 29.3 39.3 0.7 (0.4, 1.2)
Duration of use, y
<1 5.7 6.2 0.9 (0.4, 1.6) 6.5 5.4 1.0 (0.4, 2.4) 4.8 7.3 0.6 (0.2, 1.7)
≥1, <5 15.1 20.9 0.6 (0.4, 0.9) 18.0 24.0 0.6 (0.4, 1.0) 11.4 16.9 0.6 (0.3, 1.3)
≥5, <10 10.7 10.7 1.0 (0.6, 1.8) 12.4 13.6 1.0 (0.5, 1.8) 8.4 6.7 1.0 (0.4, 2.6)
≥10 12.2 16.2 0.8 (0.5, 1.2) 18.0 21.9 0.8 (0.4, 1.5) 4.8 8.4 0.6 (0.2, 1.5)
Time since last use, y
<1 31.0 39.3 0.7 (0.5, 1.1) 41.5 50.8 0.7 (0.5, 1.2) 17.4 23.6 0.6 (0.3, 1.2)
≥1, <5 6.0 4.8 1.2 (0.6, 2.3) 6.5 4.6 1.4 (0.6, 3.4) 5.4 5.1 1.0 (0.3, 3.0)
≥5, <10 1.6 2.6 0.5 (0.2, 1.4) 0.9 2.9 0.2 (0.04, 1.0) 2.4 2.3 0.9 (0.2, 4.1)
≥10 5.2 7.4 0.7 (0.4, 1.4) 6.0 6.6 0.8 (0.3, 1.9) 4.2 8.4 0.6 (0.2, 1.7)
Type of hormone
Estrogen only 24.5 33.8 0.8 (0.5, 1.2) 26.7 33.5 0.9 (0.5, 1.6) 21.6 34.3 0.6 (0.3, 1.1)
Progestin only 0.5 0.2 2.0 (0.2, 23.7) 0.9 0.4 1.8 (0.1, 23.2) 0.0 0.0 . . .
Estrogen and progestin 16.9 18.8 0.7 (0.4, 1.1) 24.4 28.9 0.6 (0.4, 1.0) 7.2 5.0 0.9 (0.3, 2.4)
Estrogen and progestin, 1.8 1.2 1.5 (0.4, 5.1) 2.8 2.1 1.2 (0.3, 4.6) 0.6 0.0 . . .
never simultaneously
Type of estrogen
Conjugated estrogens 31.9 39.4 0.8 (0.5, 1.1) 40.5 47.7 0.8 (0.5, 1.2) 21.0 28.1 0.7 (0.4, 1.3)
Other oral estrogen 2.6 3.6 0.6 (0.3, 1.5) 4.2 5.0 0.6 (0.2, 1.7) 0.6 1.7 0.4 (0.04, 4.8)
Transdermal estrogen 1.8 0.9 1.7 (0.5, 6.5) 1.9 0.8 2.5 (0.4, 15.3) 1.8 1.1 0.9 (0.1, 6.4)
Multiple estrogens 6.0 8.8 0.6 (0.3, 1.1) 6.5 9.5 0.7 (0.3, 1.6) 5.4 7.9 0.4 (0.1, 1.1)
Unknown type 1.1 1.2 0.7 (0.2, 2.9) 1.4 1.7 0.5 (0.1, 2.6) 0.6 0.6 1.4 (0.1, 27.1)
Conjugated estrogen 
dose, mg
≤0.625 21.0 27.7 0.7 (0.5, 1.1) 26.5 34.5 0.7 (0.4, 1.1) 14.4 19.0 0.7 (0.4, 1.5)
>0.625 7.7 9.8 0.8 (0.4, 1.5) 8.7 11.0 0.7 (0.3, 1.5) 6.5 8.2 1.0 (0.3, 2.9)
Multiple doses 4.1 3.9 1.0 (0.4, 2.4) 7.0 7.0 0.9 (0.4, 2.3) 0.7 0.0 . . .
Unknown dose 3.3 4.7 0.7 (0.3, 1.6) 4.9 5.0 0.9 (0.3, 2.5) 1.3 4.4 0.3 (0.1, 1.8)
Note. CI=confidence interval.
aAdjusted for age, race, type of menopause (natural, bilateral oophorectomy, other), age at menarche, number of full-term pregnancies, lactation 
history, history of breast cancer in a first-degree relative, body mass index quartiles, education, alcohol consumption, and smoking.
bCovariates were the same as for all women, except the race term was excluded from the model.
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Our findings of no increased risk of
breast cancer associated with menopausal hor-
mone use are inconsistent with conclusions
reached by the collaborative reanalysis and
2 major US cohort studies.5,16,17 This outcome
may be the result of having few long-term
users in our population. However, several
other studies that were larger than the Carolina
Breast Cancer Study also found no increased
risk of invasive breast cancer associated with
hormone use.18–20 It has been suggested that
many biases inherent in observational studies,
particularly those related to who receives hor-
mone therapy, would tend to underestimate the
risk of breast cancer associated with hormone
replacement therapy.21 Therefore, although our
point estimates were generally less than 1, it is
conceivable that a modest increase in risk was
obscured by biases that could not be fully ad-
dressed within observational studies.
Although no important racial differences
were seen in the association between hor-
mone use and breast cancer, our descriptive
analyses show striking differences between
Black and White women in patterns of hor-
mone use. Among controls, 65% of the White
women but only 39% of the Black women
had used menopausal hormones. Notably,
nearly one quarter of Black women who had
had a bilateral oophorectomy reported no hor-
mone use. Similar racial differences in hor-
mone use have been reported previously.14
The racial variation in hormone use may
be attributable to both patient and physician
factors. Although Black women report meno-
pausal symptoms as frequently as White
women do, they perceive the symptoms as
less bothersome.22,23 In addition, Black
women may rely more on family members
than medical professionals for some health
care needs and information.24 Therefore, they
may request hormones for menopausal
symptoms from physicians less often than do
White women.
Menopausal symptoms, of course, rep-
resent only one indication for hormonal ther-
apy. We had no data on the reasons that
women took hormones; however, the lower
prevalence and shorter duration of use among
Black women suggest that hormones were
prescribed less frequently for preventive rea-
sons. In this population, Black women had
lower socioeconomic status as measured by
education or income than White women did.
Some studies report that physicians are less
likely to recommend preventive measures to
poorer women because of cost concerns.25
However, because menopausal hormones
may be most beneficial among women at
higher risk for cardiovascular disease26 and
Black women have a higher prevalence of
cardiovascular risk factors,9 greater use of
hormones may be warranted.
In conclusion, breast cancer risk was not
increased among Black or White women who
used menopausal hormones. Although mod-
estly increased breast cancer risk could have
important public health implications because
of the many women exposed, these results
should be considered in terms of the overall
risks and benefits. Many researchers have
concluded that the benefits outweigh the
risks for most women,26–29 yet fear of cancer
leads many women to discontinue or never
begin hormone therapy.30,31 Physicians must
thoroughly explain expected benefits, risks,
and side effects when prescribing hormones,
allowing women to make informed decisions
about hormonal therapy for menopausal
symptoms and prevention of osteoporosis
and cardiovascular disease.
Contributors
P. G. Moorman, R. C. Millikan, and B. Newman de-
signed and directed the Carolina Breast Cancer Study
and developed the analysis strategies. H. Kuwabara
performed the statistical analyses. P.G. Moorman su-
pervised the data analysis and wrote the paper with
input provided by each of the other authors.
Acknowledgments
This work was supported by a Specialized Program
of Research Excellence (SPORE) in Breast Cancer
grant (P50-CA58223) and a FIRST award (R29-
CA67285) (P.G.M.), both funded by the National
Cancer Institute.
The authors wish to thank the Carolina Breast
Cancer Study nurse–interviewers: Carolyn Dun-
more, Dianne Mattingly, Cheryl Robinson, Theresa
Nalevaiko, and Patricia Plummer.
The study protocol of the Carolina Breast
Cancer Study was approved by the human subjects
committee of the University of North Carolina
School of Medicine and the participating hospitals.
Signed informed consent was given by all inter-
viewed women.
References
1. Speroff L. Postmenopausal hormone therapy
and the risk of breast cancer. Maturitas. 1999;
32:123–129.
2. Steinberg KK, Thacker SB, Smith SJ, et al. A
meta-analysis of the effect of estrogen replace-
ment therapy on the risk of breast cancer.
JAMA. 1991;265:1985–1990.
3. Sillero-Arenas M, Delgado-Rodriquez M,
Rodigues-Canteras R, Bueno-Cavanillas A,
Galvez-Vargas R. Menopausal hormone re-
placement therapy and breast cancer: a meta-
analysis. Obstet Gynecol. 1992;79:286–294.
4. Colditz GA, Egan KM, Stampfer MJ. Hormone
replacement therapy and risk of breast cancer:
results from epidemiologic studies. Am J Obstet
Gynecol. 1993;168:1473–1480.
5. Collaborative Group on Hormonal Factors in
Breast Cancer. Breast cancer and hormone re-
placement therapy: collaborative reanalysis of
data from 51 epidemiological studies of
52,705 women with breast cancer and 108,411
women without breast cancer. Lancet. 1997;
350:1047–1059.
6. Elledge RM, Clark GM, Chamness GC, Os-
borne CK. Tumor biologic factors and breast
cancer prognosis among White, Hispanic, and
Black women in the United States. J Natl Can-
cer Inst. 1994;86:705–712.
7. Millikan RC, Pittman GS, Tse C-KJ, et al. Cate-
chol-O-methyltransferase and breast cancer
risk. Carcinogenesis. 1998;19:1943–1947.
8. Bailey LR, Roodi N, Dupont WD, Parl FF. Asso-
ciation of cytochrome P450 1B1 (CYP1B1)
polymorphism with steroid receptor status in
breast cancer. Cancer Res. 1998;58:5038–5041.
9. Hutchinson RG, Watson RL, Davis CE, et al.,
for the ARIC Study Group. Racial differences
in risk factors for atherosclerosis. Angiology.
1997;48:279–290.
10. Newman B, Moorman PG, Millikan R, et al. The
Carolina Breast Cancer Study: integrating popu-
lation-based epidemiology and molecular biol-
ogy. Breast Cancer Res Treat. 1995;35:51–60.
11. Aldrich TE, Vann D, Moorman PG, Newman
B. Rapid reporting of cancer incidence in a
population-based study of breast cancer: one
constructive use of a central cancer registry.
Breast Cancer Res Treat. 1995;35:61–64.
12. Weinberg CR, Sandler DP. Randomized recruit-
ment in case-control studies. Am J Epidemiol.
1991;134:421–432.
13. Moorman PG, Newman B, Millikan RC, Tse C-
KJ, Sandler DP. Participation rates in a case-
control study: the impact of age, race, and race
of interviewer. Ann Epidemiol. 1999;9:188–195.
14. Brett KM, Madans JH. Use of postmenopausal
hormone replacement therapy: estimates from a
nationally representative cohort study. Am J
Epidemiol. 1997;145:536–545.
15. Rosenberg L, Palmer JR, Rao RS, Adams-
Campbell LL. Correlates of postmenopausal
female hormone use among black women in
the United States. Obstet Gynecol. 1998;91:
454–458.
16. Colditz GA, Hankinson SE, Hunter DJ, et al.
The use of estrogens and progestins and the risk
of breast cancer in postmenopausal women. N
Engl J Med. 1995;332:1589–1593.
17. Folsom AR, Mink PJ, Sellers TA, Hong C-P,
Zheng W, Potter JD. Hormonal replacement ther-
apy and morbidity and mortality in a prospective
study of postmenopausal women. Am J Public
Health. 1995;85:1128–1132.
18. Newcomb PA, Longnecker MP, Storer BE, et al.
Long-term hormone replacement therapy and
risk of breast cancer in postmenopausal women.
Am J Epidemiol. 1995;142:788–795.
19. Stanford JL, Weiss NS, Voigt LF, Daling JR,
Habel LA, Rossing MA. Combined estrogen
and progestin hormone replacement therapy in
relation to risk of breast cancer in middle-aged
women. JAMA. 1995;274:137–142.
20. Schairer C, Byrne C, Keyl PM, Brinton LA,
Sturgeon SR, Hoover RN. Menopausal estrogen
and estrogen-progestin replacement therapy and
risk of breast cancer (United States). Cancer
Causes Control. 1994;5:491–500.
21. Barrett-Connor E. Postmenopausal estrogen
and the risk of breast cancer. Ann Epidemiol.
1994;4:177–180.
22. Pham K-TC, Grisso JA, Freeman EW. Ovarian
aging and hormone replacement therapy. J Gen
Intern Med. 1997;12:230 –236.
23. Holmes-Rovner M, Padonu G, Kroll J, et al.
African-American women’s attitudes and ex-
American Journal of Public Health 971
Briefs
pectations of menopause. Am J Prev Med.
1996;12:420–423.
24. Rousseau ME, McCool WF. The menopausal
experience of African American women:
overview and suggestions for research. Health
Care Women Int. 1997;18:233–250.
25. Smith RA, Haynes S. Barriers to screening for
breast cancer. Cancer. 1992;69:1968–1978.
26. Col NF, Eckman MH, Karas RH, et al. Patient-
specific decisions about hormone replacement
therapy in postmenopausal women. JAMA.
1997;277:1140–1147.
27. Smith HO, Kammerer-Doak DN, Barbo DM,
Sarto GE. Hormone replacement therapy in the
menopause: a pro opinion. CA Cancer J Clin.
1996;46:343–363.
28. Lip GY, Beevers G, Zarif is J. Hormone re-
placement therapy and cardiovascular risk: the
cardiovascular physicians’ viewpoint. J Intern
Med. 1995;238:389–399.
29. Lobo RA. Benefits and risk of estrogen replace-
ment therapy. Am J Obstet Gynecol. 1995;173:
982– 990.
30. Nachtigall LE. Enhancing patient compliance
with hormone replacement therapy at menopause.
Obstet Gynecol. 1990;75:77S–80S.
31. Samsioe G. Hormone replacement therapy: as-
pects of bleeding problems and compliance. Int
J Fertil Menopausal Stud. 1996;41:11–15.
Objectives. This study assessed
acute hazards to young children from
pesticides toxic enough to require
child-resistant packaging.
Methods. The names of pesticides
meeting acute toxicity criteria were as-
certained from the Environmental Pro-
tection Agency. Poison Control Center
reports identif ied children younger
than 6 years who were exposed to these
pesticides. Toxicity category, medical
outcome, sex, and age were examined.
Results. A higher proportion of
children with exposure to the more toxic
products had serious medical outcomes.
Children 2 years and younger were the
predominant age group exposed.
Conclusions. Protective mea-
sures—substituting less lethal pesti-
cides, reducing the concentration of
the active ingredients, and improving
packaging and storage—are recom-
mended. (Am J Public Health. 2000;
90:971–973)
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Acute Hazards to Young Children From
Residential Pesticide Exposures
Since 1981, under the Federal Insecti-
cide, Fungicide, and Rodenticide Act, the En-
vironmental Protection Agency (EPA) has re-
quired that all highly toxic residential-use
pesticides, including disinfectants, be in
child-resistant packaging.1 Child-resistant
packaging is designed to prevent most chil-
dren younger than 5 years from gaining ac-
cess to the pesticide. It is required for any res-
idential-use product that has an estimated
acute oral median lethal dose (LD50) of 1500
mg/kg or less, has an estimated acute dermal
LD50 of 2000 mg/kg or less, has an estimated
acute median lethal concentration (LC50) of 2
mg/L or less, is corrosive to the eyes or skin,
or causes severe, persistent irritation to the
eyes or skin.
The overwhelming majority of products
in child-resistant packaging are included in
EPA Toxicity Category I (signal word “Dan-
ger” on the label) or Toxicity Category II
(signal word “Warning” on the label). For
example, a taste (1/7 of a teaspoon) of a Tox-
icity I product could kill 50% of children
weighing 10 kg (22 lb, the typical weight of
a 1-year-old child). For Toxicity Category II
products, the corresponding lethal dose for
50% of children would be 1 teaspoon. Test-
ing is performed on the formulated product,
including inert ingredients, to determine the
toxicity category.
Methods
The brand names of all Toxicity Cate-
gory I and II pesticides registered for home
use were identified from EPA electronic
files. The major classes of pesticides include
insecticides, herbicides, rodenticides, and
fungicides (including disinfectants).
This list of brand names was used to
search for cases of children (younger than
6 years) exposed to pesticides that were re-
ported to the Toxic Exposure Surveillance
System (TESS), maintained by the American
Association of Poison Control Centers.
TESS is a national database that contains
data on exposure and poisoning incidents
voluntarily reported by the public and health
care providers. Poison Control Centers par-
ticipating in TESS covered an estimated
79% of the US population from 1993
through 1995, the years for which data were
obtained.2–4 The TESS case reports include
information on the age and sex of the victim,
the product involved, the medical outcome,
and the type of medical care received. Three
years of data were searched, so that several
hundred observations for selected categories
(e.g., age, sex, toxicity) would permit statis-
tical comparisons.
The distribution of acute medical out-
comes for the children exposed to Toxicity
Category I and II pesticide products was
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